Forget the Cash ISA. Here are 2 FTSE 100 stocks I’d buy and hold forever

These FTSE 100 (INDEXFTSE: UKX) income champions yield nearly three times as much as the best Cash ISA on the market today says Rupert Hargreaves.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the best Cash ISA on the market today offering an interest rate of just 1.5%, I think it’s best to overlook this meagre level of income and invest your money in shares instead.

Indeed, the FTSE 100 is full of blue-chip income stocks that offer both a higher rate of income and the potential for capital gains as well. Today I’m going to highlight just two of these FTSE 100 income and growth champions.

Buy-and-hold

AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) both offer a highly attractive combination of income and growth. At the same time, these two pharmaceutical businesses are extremely defensive. The global healthcare market is only growing, and it isn’t subject to cyclical factors like so many other industries, so I think I am quite safe in saying that these companies will still be around 50 years from now doing what they do best, developing, producing and selling treatments for patients all over the world.

Both Astra and Glaxo are experts in their respective fields. Over the past few years, Glaxo has been building out its consumer healthcare products business, which produces and supplies products such as Sensodyne toothpaste and Panadol. In December 2018, the company announced an agreement with US drugs giant Pfizer to form a world-leading consumer healthcare joint venture, which the partners aim to spin off within three years.

This transaction could potentially unlock billions of dollars in value for Glaxo’s shareholders as analysts have said many times in the past that they believe the component parts of Glaxo are worth more apart than they are together.

The company also owns a share in ViiV Healthcare, a world leader in the development and production of HIV medication and Glaxo is a world leader in the production of vaccines.

Astra, meanwhile, has carved out a niche for itself in the oncology market. Management has been focusing its efforts on this fast-growing market for the past few years, and now the company is bringing a number of new treatments to market which could end up becoming multibillion-dollar anti-cancer drugs. For the first quarter of 2019 overall product sales leapt 14% at constant exchange rates, led by a 59% increase in sales at the group’s oncology business. 

The future is exciting

The future for both of these companies is exciting and I think shareholders will be well rewarded over the next five to 10 years as Astra’s oncology pipeline starts to yield results and Glaxo spins off its consumer healthcare business.

In the meantime, shareholders can pick up a market-beating dividend yield from both. At the time of writing, shares in Glaxo support a dividend yield of 5.1% and shares in Astra yield 3.6%. Shares in both businesses are not particularly expensive either. Glaxo trades at a forward P/E of just 14, compared to the UK pharmaceutical industry average of 18.6, and Astra is dealing at a 2020 P/E of 17.9.

So overall, if you are looking to break free from the world of the low returns in the Cash ISA market, then I think it is worth checking out Astra and Glaxo for their defensive qualities, attractive valuations and market-beating dividend yields.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »